Breaking news from ASCO 2022 : PIPAC with cisplatin and doxorubicin is superior to intravenous chemotherapy in platin-resistant ovarian cancer.
Click here for more details
CapnoPharm is a young and successful medical technology company focusing on the development of innovative processes involving medical aerosols.
Our science relies on a growing body of evidence around PIPAC (Pressurized Intraperitoneal Aerosol Chemotherapy), an intraoperative aerosol drug delivery system. Pipac provides numerous avenues for research and development in oncology – from re-formulation of existing chemotherapy drugs to next-generation drugs involving Nanoparticles, mRNA or Immunotherapeutics.
Together with our pharmaceutical clients, we explore the drug-device synergies which could shape the future of cancer care. In doing so, we are devoted to our mission of improving the health and well-being of cancer patients around the world, for the best possible quality of life.